Mitchell Sinkler & Starr PA Sells 42,813 Shares of Johnson & Johnson $JNJ

Mitchell Sinkler & Starr PA decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 66.1% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 22,006 shares of the company's stock after selling 42,813 shares during the period. Johnson & Johnson comprises 1.6% of Mitchell Sinkler & Starr PA's portfolio, making the stock its 15th biggest position. Mitchell Sinkler & Starr PA's holdings in Johnson & Johnson were worth $3,361,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $35,000. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $48,000. Finally, von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $49,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.0%

JNJ stock opened at $190.88 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $459.70 billion, a PE ratio of 20.41, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The business's 50 day simple moving average is $179.28 and its 200 day simple moving average is $164.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $24.02 billion for the quarter. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an "overweight" rating in a research report on Friday, October 3rd. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Weiss Ratings raised Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, October 8th. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, Sanford C. Bernstein boosted their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a "market perform" rating in a report on Monday, October 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $193.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.